An official website of the United States government
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Trial Status: active
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant
Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step
radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess
safety and tolerability
Inclusion Criteria
Signed informed consent from patient, legal guardian(s) and/or adolescents obtained in accordance with local regulations. Pediatric patients must provide assent as required by local regulations.
Age ≥18 years at the time of informed consent, for High Risk Neuroblastoma & sarcoma age ≥16 years of age at time of informed consent/assent
Measurable disease according to RECIST 1.1
ECOG performance status 0-1
Expected survival >3 months
Platelet counts ≥100,000 cells/mm3
Hemoglobin ≥9 g/dL
Adequate renal function with serum creatinine ≤1.5 mg/dL or creatinine clearance ≥60mL/min as calculated using the Cockcroft-Gault equation
Patient willing and able to comply with the trial protocol
Exclusion Criteria
Systemic chemotherapy, radiotherapy, immunotherapy, or major surgery administered within 3 weeks prior to the first planned dosing of the IMP per protocol
Patients receiving any other investigational therapy for their cancer within 3 weeks prior to the first planned dosing of the IMP per protocol
Ongoing radiation toxicities from prior RT therapy
Patients with a diagnosis of autoimmune diseases or immunodeficiencies or documented infection with human immunodeficiency virus (HIV) or hepatitis B or C virus (active)
Prior treatment with anti-GD2 antibody
Additional locations may be listed on ClinicalTrials.gov for NCT05130255.
